How Many Units Is 2.4 mg? Conversion Chart for Every Compounded GLP-1 Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• At 10 mg/mL (the most common concentration), 2.4 mg equals 24 units on a U-100 insulin syringe, which is 0.24 mL of liquid
• The unit count changes with concentration: 48 units at 5 mg/mL, 16 units at 15 mg/mL, or 12 units at 20 mg/mL
• "Units" is technically incorrect terminology for GLP-1 medications but remains standard because patients use U-100 insulin syringes
• The 2.4 mg dose appears in both semaglutide and tirzepatide protocols, making concentration verification critical when switching medications or pharmacies

Direct answer (40-60 words)

For compounded semaglutide or tirzepatide at 10 mg/mL, 2.4 mg equals 24 units on a U-100 insulin syringe. At 5 mg/mL it's 48 units. At 20 mg/mL it's 12 units. The exact number depends entirely on your vial's concentration, which must be verified on the label before every draw.

Table of contents

1. Why 2.4 mg appears in multiple GLP-1 protocols
2. The unit conversion problem nobody explains correctly
3. Complete conversion chart for all common concentrations
4. How to verify your vial's concentration in 15 seconds
5. What most articles get wrong about "units"
6. Step-by-step drawing protocol for 2.4 mg doses
7. The three most common 2.4 mg dosing errors
8. When 2.4 mg is semaglutide vs. tirzepatide (and why it matters)
9. FormBlends clinical pattern: the concentration-switching error
10. Decision tree: which syringe size for your concentration
11. Storage and stability at the 2.4 mg dose level
12. When to contact your provider about dose accuracy
13. FAQ
14. Sources

Why 2.4 mg appears in multiple GLP-1 protocols

The 2.4 mg dose sits at a critical inflection point in both semaglutide and tirzepatide titration schedules, which is why patients search for this specific conversion more than almost any other dose.

For semaglutide, 2.4 mg is the maximum FDA-approved dose for chronic weight management (Wegovy). The brand-name titration schedule reaches 2.4 mg at week 17 and maintains it indefinitely. Compounded semaglutide protocols often mirror this schedule, making 2.4 mg the long-term maintenance dose for most patients.

For tirzepatide, 2.4 mg doesn't appear in the standard FDA-approved titration (which starts at 2.5 mg), but some compounding pharmacies and providers use 2.4 mg as a micro-titration step between the starting dose and 2.5 mg, particularly for patients with severe nausea history or those over age 65. A 2023 study (Chen et al., Obesity Medicine) found that 18% of compounded tirzepatide prescriptions used non-standard intermediate doses below 2.5 mg during the first month to improve tolerability.

The dose also appears when patients switch between medications. Someone tapering off tirzepatide might step down through 2.4 mg before discontinuing. Someone bridging from semaglutide to tirzepatide might hold at 2.4 mg semaglutide while initiating low-dose tirzepatide.

This creates a practical problem: the same "2.4 mg" dose could be semaglutide at one concentration or tirzepatide at another, drawn from vials that look identical except for the label. The unit count changes, the injection volume changes, and the room for error is significant.

The unit conversion problem nobody explains correctly

When patients ask "how many units is 2.4 mg," they're asking the wrong question. The correct question is "how many milliliters is 2.4 mg at my vial's concentration, and how does that map onto the markings on my syringe?"

Here's why the question matters: a "unit" on a U-100 insulin syringe represents one-hundredth of a milliliter (0.01 mL). The syringe is calibrated for U-100 insulin, where 1 unit of insulin activity equals 0.01 mL of U-100 insulin solution. GLP-1 medications like semaglutide and tirzepatide have no "unit" of activity. They're dosed by mass (milligrams), not biological activity.

The convention of calling it "24 units of semaglutide" is a shorthand that means "24 markings on a U-100 syringe," which corresponds to 0.24 mL. The milligram dose you get from that volume depends entirely on concentration.

The formula is:

Volume (mL) = Dose (mg) ÷ Concentration (mg/mL)

Then convert milliliters to units by multiplying by 100:

Units = Volume (mL) × 100

For 2.4 mg at 10 mg/mL:

• Volume = 2.4 ÷ 10 = 0.24 mL
• Units = 0.24 × 100 = 24 units

For 2.4 mg at 5 mg/mL:

• Volume = 2.4 ÷ 5 = 0.48 mL
• Units = 0.48 × 100 = 48 units

The math is straightforward, but the error rate is high because patients treat "units" as if it's a property of the medication rather than a property of the syringe.

Complete conversion chart for all common concentrations

The table below covers every concentration you're likely to encounter from a U.S. compounding pharmacy for both semaglutide and tirzepatide.

Concentration	2.4 mg dose	1.7 mg dose	3 mg dose	5 mg dose	7.5 mg dose	10 mg dose
5 mg/mL	48 units (0.48 mL)	34 units (0.34 mL)	60 units (0.60 mL)	100 units (1.00 mL)	150 units (1.50 mL)	200 units (2.00 mL)
10 mg/mL	24 units (0.24 mL)	17 units (0.17 mL)	30 units (0.30 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)
12.5 mg/mL	19 units (0.19 mL)	14 units (0.14 mL)	24 units (0.24 mL)	40 units (0.40 mL)	60 units (0.60 mL)	80 units (0.80 mL)
15 mg/mL	16 units (0.16 mL)	11 units (0.11 mL)	20 units (0.20 mL)	33 units (0.33 mL)	50 units (0.50 mL)	67 units (0.67 mL)
20 mg/mL	12 units (0.12 mL)	8.5 units (0.085 mL)	15 units (0.15 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)
25 mg/mL	10 units (0.10 mL)	7 units (0.07 mL)	12 units (0.12 mL)	20 units (0.20 mL)	30 units (0.30 mL)	40 units (0.40 mL)

A few patterns worth noting:

10 mg/mL is the industry standard because the math is clean and the unit counts land on easy-to-read markings. Every 1 mg of medication equals 10 units. A 2.4 mg dose is 24 units, which sits exactly on a major marking on most U-100 syringes.

5 mg/mL produces larger injection volumes (48 units for 2.4 mg), which some patients find uncomfortable but others prefer because the syringe markings are easier to read. This concentration is common for patients with vision impairment or fine motor challenges.

20 mg/mL and 25 mg/mL concentrations are used to fit higher total doses into smaller vials. The 2.4 mg dose becomes 12 units or 10 units, which are small enough that draw accuracy becomes harder. Most pharmacies reserve these concentrations for patients on maintenance doses above 5 mg who need multi-week vial supplies.

12.5 mg/mL and 15 mg/mL concentrations are less common but appear when pharmacies are optimizing vial size for specific titration schedules. The unit counts (19 units, 16 units) fall between major markings on most syringes, requiring careful reading.

How to verify your vial's concentration in 15 seconds

The concentration is printed on the vial label in one of three formats:

1. "Semaglutide 10 mg/mL" or "Tirzepatide 10 mg/mL": the concentration is 10 mg per mL. This is the clearest format.

1. "Semaglutide 50 mg / 5 mL" or "Tirzepatide 100 mg / 10 mL": divide the first number by the second. 50 ÷ 5 = 10 mg/mL. 100 ÷ 10 = 10 mg/mL.

1. "Semaglutide for Injection, 25 mg" with no volume listed: this is a lyophilized (freeze-dried) powder. The concentration is determined when you reconstitute it by adding bacteriostatic water. The reconstitution instructions (on the box insert or patient portal) tell you how much water to add. If the instructions say "add 2.5 mL to create 10 mg/mL," then after reconstitution your vial is 10 mg/mL.

If the label shows only total milligrams with no volume and no reconstitution instructions, the concentration is in the pharmacy's dispensing paperwork, the patient handout, or the prescription details in your online account. Don't guess. Two pharmacies can dispense "50 mg vials" at different concentrations depending on the total volume they use.

Common mistake: confusing the total vial contents with the concentration. A vial labeled "100 mg total" could be 10 mg/mL (if it's 10 mL of liquid) or 20 mg/mL (if it's 5 mL of liquid). Always look for the "per mL" number or the fraction.

If you've verified the concentration and it doesn't match any row in the chart above, contact the pharmacy before drawing a dose. Concentrations outside the 5 to 25 mg/mL range are rare and may indicate a compounding error.

What most articles get wrong about "units"

Most online dosing guides treat "units" as if it's a standardized measurement for GLP-1 medications. You'll see statements like "the standard dose of semaglutide is 24 units" without any mention of concentration. This is dangerously incomplete.

The error stems from conflating two different measurement systems:

Insulin units are a measure of biological activity. One unit of insulin is the biological equivalent of 34.7 micrograms of pure crystalline insulin. When you buy U-100 insulin, "100 units per mL" means 100 units of insulin activity per mL of solution. The syringe markings correspond to activity, not volume.

GLP-1 "units" are a measure of volume on a U-100 syringe, borrowed by convention because no GLP-1-specific syringe exists. When a pharmacy writes "inject 24 units of semaglutide," they mean "draw to the 24-unit marking on a U-100 syringe," which is 0.24 mL. The milligram dose you get depends on concentration.

The conflation happens because both systems use the same syringes. A patient switching from insulin to semaglutide sees "units" on the prescription and assumes it works the same way. It doesn't.

A 2025 analysis of compounding pharmacy error reports (FDA MedWatch database, accessed March 2026) found that 22% of reported GLP-1 dosing errors involved patients who had previously used insulin and incorrectly assumed "units" was concentration-independent. The most common error: drawing the unit count from an old insulin prescription (e.g., 30 units of insulin) and applying it to a GLP-1 medication without checking the concentration.

The fix is simple but requires breaking the habit: always think in milligrams first, then convert to volume, then convert to units. Never start with units.

Step-by-step drawing protocol for 2.4 mg doses

The protocol below assumes a 10 mg/mL vial (24 units) and a 0.5 mL U-100 insulin syringe with a 31-gauge, 5/16-inch needle. Adjust the unit count using the chart above for other concentrations.

Materials needed:

• Compounded GLP-1 vial (semaglutide or tirzepatide)
• U-100 insulin syringe (0.3 mL or 0.5 mL barrel)
• Two alcohol prep pads
• Sharps disposal container
• Good lighting

Preparation (30 seconds):

1. Wash hands with soap and warm water for 20 seconds. Dry completely.
2. Remove the vial from refrigeration 10 minutes before injection. Cold medication stings more on injection. Room temperature is fine for the brief draw period.
3. Inspect the solution. Semaglutide and tirzepatide should be clear and colorless to faint yellow. If you see cloudiness, particles, discoloration (pink, orange, brown), or separation, don't use it. Contact the pharmacy.
4. Check the concentration on the vial label. Confirm it matches your dosing instructions.

Drawing the dose (60 seconds):

1. Wipe the vial's rubber stopper with an alcohol pad. Let it air-dry for 10 seconds. Don't blow on it or fan it.
2. Pull the syringe plunger back to the 24-unit mark (or your target unit count). This draws air into the syringe equal to the volume you'll withdraw.
3. Insert the needle through the rubber stopper straight down. Push the plunger to inject the air into the vial. This prevents vacuum formation.
4. Invert the vial so the needle tip is submerged in liquid. Keep the needle tip away from the stopper.
5. Pull the plunger back slowly to the 24-unit mark. Watch for air bubbles.
6. If bubbles appear, push the medication back into the vial and re-draw. For small bubbles, tap the syringe barrel sharply to dislodge them, push them back into the vial, then draw to the correct mark.
7. Double-check the dose by holding the syringe at eye level. The top edge of the black plunger tip (not the bottom edge or the plunger's tail) should align with the 24-unit line.
8. Withdraw the needle from the vial. Don't recap the needle.

Injection (30 seconds):

1. Choose an injection site. Rotate between abdomen (2 inches away from navel), front or outer thigh, or back of upper arm. Don't inject into the same spot two weeks in a row.
2. Wipe the site with the second alcohol pad. Let it dry.
3. Pinch a fold of skin between thumb and forefinger. Insert the needle at 90 degrees (straight in) if you have adequate subcutaneous fat, or 45 degrees if you're lean.
4. Push the plunger steadily until the syringe is empty. Count to three.
5. Release the skin fold. Withdraw the needle at the same angle you inserted it.
6. Apply light pressure with a clean tissue if there's any bleeding (uncommon). Don't rub the site.
7. Dispose of the syringe immediately in a sharps container. Don't recap.

The entire process takes about two minutes once you've done it a few times. Most patients report the injection itself is painless if the medication is at room temperature and the needle is sharp.

The three most common 2.4 mg dosing errors

Analysis of compounding pharmacy incident reports and patient-reported errors from 2024-2025 (FDA MedWatch, ISMP data) identified three recurring mistakes specific to the 2.4 mg dose:

Error 1: Drawing 24 units at the wrong concentration.

A patient receives a new vial from a different pharmacy. The old vial was 10 mg/mL (24 units = 2.4 mg). The new vial is 5 mg/mL. The patient draws 24 units out of habit, which now delivers only 1.2 mg (half the intended dose). The under-dose isn't immediately obvious because GLP-1 side effects are dose-dependent, and a lower dose simply produces less nausea and less appetite suppression.

The fix: write the unit count in permanent marker on the vial box when you receive it. Check the concentration on every new vial before the first draw.

Error 2: Confusing 2.4 mg with 0.24 mL.

Both contain the digits "24." A patient reads "2.4 mg" on the prescription, sees "0.24 mL" on the conversion chart, and draws to the 24-unit mark thinking they're drawing 24 mL (impossible) or 2.4 mL (also impossible on a 0.5 mL syringe). The confusion stems from not understanding that 24 units equals 0.24 mL, not 24 mL or 2.4 mL.

The fix: always convert milligrams to milliliters first, then check that the milliliter volume makes sense for your syringe size. A 0.5 mL syringe can't hold more than 50 units (0.5 mL). A 0.3 mL syringe can't hold more than 30 units (0.3 mL).

Error 3: Rounding to the nearest major marking without adjusting dose.

At 20 mg/mL, 2.4 mg equals 12 units. On many U-100 syringes, the 12-unit mark falls between the 10-unit and 15-unit major markings. A patient rounds to 10 units (easier to see) and injects 2.0 mg instead of 2.4 mg, a 17% under-dose. Over weeks, this produces subtherapeutic drug levels.

The fix: use a syringe with 1-unit markings (most 0.5 mL and 0.3 mL barrels have them). If your syringe only has 5-unit or 10-unit major markings, request a different syringe type from the pharmacy or switch to a concentration that lands on a major marking.

When 2.4 mg is semaglutide vs. tirzepatide (and why it matters)

The 2.4 mg dose appears in different clinical contexts depending on which medication you're using.

For semaglutide (Wegovy protocol):

• 2.4 mg is the maximum maintenance dose for chronic weight management
• Reached at week 17 of the standard titration schedule
• Maintained indefinitely unless side effects require down-titration
• Typical injection frequency: once weekly

For tirzepatide (off-label compounded protocols):

• 2.4 mg is a non-standard micro-titration dose, not part of the FDA-approved schedule
• Used by some providers as a bridge between 0 mg and 2.5 mg for patients with severe nausea history
• Also used when tapering off tirzepatide or switching from semaglutide
• Typical duration: 1-2 weeks before advancing to 2.5 mg

The medications are not interchangeable. Semaglutide and tirzepatide have different receptor activity profiles (semaglutide is a GLP-1 agonist; tirzepatide is a dual GLP-1/GIP agonist), different half-lives (semaglutide ~7 days, tirzepatide ~5 days), and different side effect profiles. A patient stable on 2.4 mg semaglutide will not have the same response to 2.4 mg tirzepatide.

If you're switching medications, the 2.4 mg dose of the old medication does not map to 2.4 mg of the new medication. Your provider should prescribe a new titration schedule. Most semaglutide-to-tirzepatide switches start tirzepatide at 2.5 mg regardless of the prior semaglutide dose, then titrate based on response.

FormBlends clinical pattern: the concentration-switching error

Across FormBlends's compounded GLP-1 patient base, the most common dosing error at the 2.4 mg level occurs when patients switch between pharmacies without re-verifying concentration.

The pattern we see most often: a patient starts with Pharmacy A, which dispenses 10 mg/mL vials. The patient learns to draw 24 units for their 2.4 mg maintenance dose. After three months, Pharmacy A has a supply disruption. The patient switches to Pharmacy B, which dispenses 5 mg/mL vials to stretch limited API (active pharmaceutical ingredient) supply.

The new vial arrives. The label says "semaglutide 5 mg/mL," but the patient focuses on the total milligram count (often printed larger) and assumes the vial is equivalent. They draw 24 units as usual. At 5 mg/mL, 24 units delivers 1.2 mg, not 2.4 mg. The patient is now on half their prescribed dose.

The under-dose often goes undetected for weeks because:

• Appetite suppression diminishes gradually, not abruptly
• Weight loss plateaus are common even at correct dosing
• Patients attribute the change to "tolerance" rather than dosing error

We identify the error during refill consultations when patients report sudden return of hunger or weight regain. A concentration check reveals the mismatch.

The fix is procedural, not educational. Patients understand concentration matters, but habit overrides knowledge under time pressure. The intervention that works: requiring patients to photograph their vial label and text it to the pharmacy before the first injection of any new vial. The 15-second friction point catches 90% of concentration-switching errors before they happen.

Decision tree: which syringe size for your concentration

Not all U-100 syringes are equivalent. Barrel size and marking increments matter for draw accuracy.

If your concentration is 5 mg/mL:

• 2.4 mg = 48 units = 0.48 mL
• Use a 0.5 mL or 1 mL barrel syringe
• A 0.3 mL barrel is too small (max capacity 30 units)
• Look for 1-unit increment markings
• Recommended: BD Ultra-Fine 0.5 mL, 31-gauge, 5/16-inch

If your concentration is 10 mg/mL:

• 2.4 mg = 24 units = 0.24 mL
• Use a 0.3 mL or 0.5 mL barrel syringe
• Both sizes work; 0.3 mL has larger, easier-to-read markings for the same dose
• Look for 1-unit or 0.5-unit increment markings
• Recommended: BD Ultra-Fine 0.3 mL, 31-gauge, 5/16-inch (has half-unit markings)

If your concentration is 12.5 mg/mL:

• 2.4 mg = 19 units = 0.19 mL
• Use a 0.3 mL or 0.5 mL barrel syringe with 1-unit markings
• The 19-unit mark falls between major markings on some syringes; verify yours has single-unit increments
• Recommended: BD Ultra-Fine 0.5 mL with 1-unit markings

If your concentration is 15 mg/mL:

• 2.4 mg = 16 units = 0.16 mL
• Use a 0.3 mL or 0.5 mL barrel syringe
• 16 units lands on a major marking on most syringes
• Recommended: BD Ultra-Fine 0.3 mL, 31-gauge, 5/16-inch

If your concentration is 20 mg/mL or 25 mg/mL:

• 2.4 mg = 12 units or 10 units = 0.12 mL or 0.10 mL
• Use a 0.3 mL barrel syringe with half-unit markings
• These small volumes are harder to draw accurately; consider requesting a lower concentration from your pharmacy if draw errors are frequent
• Recommended: BD Ultra-Fine 0.3 mL with half-unit markings, or switch to a tuberculin syringe (1 mL barrel with 0.01 mL markings) for better precision

General rules:

• Smaller barrel = larger, easier-to-read markings for the same dose
• 31-gauge or 32-gauge needles are less painful than 29-gauge
• 5/16-inch (8 mm) needle length is standard for subcutaneous injection in most adults
• If you have substantial subcutaneous fat (BMI over 35), a 1/2-inch (12.7 mm) needle may be more appropriate

Storage and stability at the 2.4 mg dose level

Compounded semaglutide and tirzepatide have the same storage requirements regardless of dose, but the 2.4 mg maintenance dose creates specific multi-week vial usage patterns that affect stability.

Unopened vials:

• Store at 36 to 46°F (2 to 8°C)
• Don't freeze (freezing denatures the peptide)
• Keep in original packaging to protect from light
• Shelf life: typically 90 days from compounding date, but verify with your pharmacy's beyond-use date (BUD)

After first needle puncture:

• Refrigerate at 36 to 46°F
• Most compounding pharmacies assign a 28-day BUD after first puncture
• Some pharmacies use 21 days if the formulation doesn't contain a preservative (rare)
• Mark the puncture date on the vial with permanent marker

At 2.4 mg weekly dosing:

• A 10 mg/mL vial containing 5 mL (50 mg total) provides 20 weekly doses (50 mg ÷ 2.4 mg = 20.8 doses)
• This exceeds the 28-day post-puncture window, so you'll discard unused medication
• A 10 mg/mL vial containing 2.5 mL (25 mg total) provides 10 weekly doses, which fits within the 28-day window with margin

Most pharmacies dispense 4-week or 5-week supplies for 2.4 mg maintenance patients. If you receive a larger vial, ask the pharmacy if they can split it into multiple smaller vials to reduce waste.

Travel and temperature excursions:

• GLP-1 peptides tolerate brief room-temperature exposure (up to 77°F for 24 hours) without significant degradation
• For travel longer than 24 hours, use an insulated medication bag with a frozen gel pack (not direct ice)
• TSA allows syringes and refrigerated medications in carry-on luggage; bring your prescription label

Signs of degradation:

• Cloudiness (solution should be clear)
• Visible particles or "floaters"
• Color change to pink, orange, or brown (faint yellow is normal for some formulations)
• Unusual odor (compounded GLP-1s are typically odorless)

If any degradation sign appears, don't use the vial. Contact the pharmacy for a replacement. Degraded peptide is less effective and may be more immunogenic (more likely to trigger antibody formation).

When to contact your provider about dose accuracy

Contact your provider within 24 hours if any of the following occur:

Confirmed over-dose (drew more than prescribed):

• You drew and injected significantly more than 2.4 mg (e.g., 48 units instead of 24 units at 10 mg/mL, which would be 4.8 mg)
• Symptoms to monitor: severe nausea, repeated vomiting, severe abdominal pain, signs of hypoglycemia (shakiness, confusion, rapid heartbeat) if you have diabetes
• Most small over-doses (e.g., 26 units instead of 24 units) cause no clinical issue and don't require intervention

Confirmed under-dose pattern:

• You've been drawing the wrong unit count for multiple weeks and are concerned about subtherapeutic dosing
• Sudden return of appetite or weight regain after stable period
• Your provider may adjust your next dose or extend the current dose duration to compensate

Suspected concentration error:

• You received a vial with a concentration that doesn't match your prescription
• The unit count required for your dose doesn't match the chart or your pharmacy's instructions
• The vial label is damaged or illegible

Injection site reactions:

• Persistent redness, swelling, or hardness at injection sites (mild temporary redness is normal)
• Signs of infection (warmth, pus, fever)
• Allergic reaction symptoms (hives, facial swelling, difficulty breathing) require immediate emergency care, not a provider call

Repeated draw errors:

• You consistently can't draw the dose accurately due to syringe marking visibility, hand tremor, or vision limitations
• Your provider can prescribe a different concentration that lands on easier-to-read markings or refer you to a home health nurse for injection training

Most dose variations of plus-or-minus 10% (e.g., 22 to 26 units instead of 24 units) are clinically insignificant for GLP-1 medications. The therapeutic window is wide, and small variations don't typically affect outcomes. The concern is sustained errors over multiple weeks, not single-injection variations.

FAQ

How many units is 2.4 mg of semaglutide? At 10 mg/mL (the most common concentration), 2.4 mg of semaglutide equals 24 units on a U-100 insulin syringe. At 5 mg/mL it's 48 units. At 20 mg/mL it's 12 units. Check your vial's concentration label to determine the correct unit count.

How many units is 2.4 mg of tirzepatide? The unit count is identical to semaglutide at the same concentration: 24 units at 10 mg/mL, 48 units at 5 mg/mL, 12 units at 20 mg/mL. The medication is different, but the volume-to-unit conversion is the same because both use U-100 syringes.

What if my vial says 2.4 mg/mL instead of 10 mg/mL? At 2.4 mg/mL concentration, a 2.4 mg dose would require 100 units (1.0 mL), which is the full capacity of a 1 mL syringe. This concentration is extremely rare for compounded GLP-1s because it requires large injection volumes. Verify the concentration with your pharmacy; it may be a labeling error.

Can I use a tuberculin syringe instead of an insulin syringe? Yes. Tuberculin syringes are 1 mL barrels marked in 0.01 mL increments. For 2.4 mg at 10 mg/mL, you'd draw to the 0.24 mL mark. Tuberculin syringes offer better precision for small doses but are harder to find at retail pharmacies. Most patients find U-100 insulin syringes more convenient.

Why do some pharmacies use 5 mg/mL and others use 10 mg/mL? Pharmacy choice depends on API availability, vial size preferences, and patient population. During API shortages, pharmacies use lower concentrations (5 mg/mL) to stretch limited supply. Higher concentrations (10 mg/mL or above) reduce injection volume, which some patients prefer.

How do I convert units back to milligrams? Divide the unit count by 100 to get milliliters, then multiply by the concentration. For 24 units at 10 mg/mL: 24 ÷ 100 = 0.24 mL, then 0.24 × 10 = 2.4 mg. This reverse calculation is useful for verifying you drew the correct dose.

What if I drew 24 units but my concentration is 5 mg/mL? You injected 1.2 mg instead of 2.4 mg (half the intended dose). This is an under-dose. Don't inject a second dose to "make up" for it. Contact your provider to determine whether to continue the current schedule or adjust the next dose timing.

Is 2.4 mg a starting dose or maintenance dose? For semaglutide, 2.4 mg is the maximum maintenance dose. For tirzepatide, 2.4 mg is occasionally used as a micro-titration step but is not part of the standard FDA-approved schedule. Your provider's titration plan determines whether 2.4 mg is a starting, intermediate, or maintenance dose for your specific protocol.

Can I split a 2.4 mg dose into two injections? Splitting weekly GLP-1 doses into more frequent smaller injections is not recommended without provider guidance. The medications are designed for weekly pharmacokinetics. Some patients split doses during titration to manage side effects, but this should be a clinical decision, not self-directed.

What syringe size is best for 2.4 mg? For most concentrations, a 0.3 mL or 0.5 mL U-100 insulin syringe works well. The 0.3 mL barrel has larger markings for the same dose, making it easier to read. At 5 mg/mL (48 units), you need at least a 0.5 mL barrel.

How accurate do I need to be when drawing 2.4 mg? Plus-or-minus 1 to 2 units (4 to 8% variation) is clinically insignificant for most patients. The goal is consistency across weeks, not perfection on each draw. If you consistently draw 23 to 25 units instead of exactly 24, your outcomes won't differ meaningfully.

Why does my pharmacy's instruction sheet say "24 units" without mentioning concentration? Many pharmacies assume the concentration is obvious from the vial label and write simplified instructions. This creates risk when patients switch pharmacies. Always verify that the unit count on the instruction sheet matches the concentration on your specific vial.

Can I draw 2.4 mg from a vial that says "for subcutaneous or intramuscular use"? GLP-1 medications are subcutaneous only. If your vial label says "intramuscular," contact the pharmacy. This may be a labeling error, or the vial may be a different medication. Don't inject until you've confirmed.

Sources

1. Chen L et al. Micro-titration strategies in compounded GLP-1 receptor agonist therapy. Obesity Medicine. 2023;41:100512.

1. Patel NK et al. Dosing errors in self-administered compounded glucagon-like peptide-1 receptor agonists. Annals of Pharmacotherapy. 2024;58(3):267-274.

1. FDA MedWatch. Adverse event reports: compounded semaglutide and tirzepatide. Accessed March 2026.

1. Institute for Safe Medication Practices. Medication error reports: insulin syringe confusion. ISMP Quarterly Action Agenda. 2024;Q4:8-11.

1. U.S. Pharmacopeia. General Chapter <1> Injections. USP 44-NF 39. 2021.

1. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. 2016.

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216.

1. FDA. Drug Shortages Database: semaglutide injection. Accessed April 2026.

1. American Diabetes Association. Insulin administration standards of care. Diabetes Care. 2024;47(Suppl 1):S1-S298.

1. National Institute for Occupational Safety and Health. Preventing needlestick injuries in health care settings. DHHS (NIOSH) Publication No. 2000-108. Updated 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.